MARKET

AQST

AQST

Aquestive Therapeutics
NASDAQ
3.930
+0.030
+0.77%
After Hours: 4.090 +0.16 +4.07% 19:58 04/25 EDT
OPEN
3.930
PREV CLOSE
3.900
HIGH
4.010
LOW
3.775
VOLUME
1.94M
TURNOVER
0
52 WEEK HIGH
6.23
52 WEEK LOW
1.150
MARKET CAP
353.57M
P/E (TTM)
-30.5837
1D
5D
1M
3M
1Y
5Y
Aquestive Therapeutics: Notice of Effectiveness
Press release · 1d ago
OPI, RVNC and AQST are among after hour movers
On the Move OPI, RVNC and AQST are among after hour movers. Cadence Design Systems and Synopsys are among the companies losing ground. Oportun Financial and Humacyte are the biggest gainers in this week's list of names on the move.
Seeking Alpha · 3d ago
Weekly Report: what happened at AQST last week (0415-0419)?
Weekly Report · 3d ago
Ally Financial Reports Upbeat Earnings, Joins Badger Meter, Genuine Parts And Other Big Stocks Moving Higher On Thursday
Ally Financial shares jumped 7.7% to $39.06 on Thursday after the company reported better-than-expected quarterly results. The Nasdaq Composite fell over 50 points in today's session. Shares of Trump Media & Technology Group Corp. Also rose sharply.
Benzinga · 04/18 17:58
Coming FDA Approvals Could Send These 3 Drug Stocks Soaring
FDA approval is the number one needle mover for drug stocks. FDA approval for a drug or treatment can bring years of steady, high-margin revenue to a company. Three companies are awaiting key FDA decisions over the next couple of months. Merck & Co, Amgen and Aquestive Therapeutics are among the companies awaiting key decisions.
Investorplace · 04/17 12:00
Weekly Report: what happened at AQST last week (0408-0412)?
Weekly Report · 04/15 11:24
Aquestive Therapeutics a new overweight at Piper on oral film products
Aquestive Therapeutics a new overweight at Piper on oral film products. The firm has a $10 price target for the stock. Piper Sandler says the company is poised for value creation through its proprietary oral film, PharmFilm, to deliver existing medicines. Piper's David Absellem likes Anaphylm, an oral film of epinephrine to treat anaphylaxis.
Seeking Alpha · 04/11 18:48
Piper starts Aquestive at overweight, cites allergy reaction treatment
Healthcare Piper starts Aquestive at overweight, cites allergy reaction treatment Anaphylm. Piper Sandler started coverage of aquestive Therapeutics with an overweight rating. The investment firm cites the market potential for its allergic reaction treatment. Piper believes data for Anaphylm supports potential FDA approval in 2025.
Seeking Alpha · 04/11 16:38
More
About AQST
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is developing pharmaceutical products to deliver complex molecules through administrations that are alternatives to invasive and inconvenient standard of care therapies. It is advancing a product pipeline for the treatment of severe allergic reactions, including anaphylaxis. It has also developed a product pipeline focused on treating diseases of the central nervous system (CNS). Its PharmFilm technology is comprised of proprietary polymer compositions that serve as film formers to hold active pharmaceutical ingredients (APIs), and excipients in place. Its product portfolio and pipeline include Anaphylm, AQST-108, and Adrenaverse. Its CNS product candidate include Libervant. The Company’s Licensed commercial products and product candidates and other product includes Suboxone, Exservan, KYNMOBI, Zuplenz, Azstarys, Libervant, and Sympazan. Anaphylm is a non-device based, orally delivered epinephrine product candidate.

Webull offers Aquestive Therapeutics Inc stock information, including NASDAQ: AQST real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AQST stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AQST stock methods without spending real money on the virtual paper trading platform.